Beijing, China, December 10, 2017 --(PR.com
)-- A Chinese firm recently announced a Cognitive Stimulation Training (CST) robot project, which uses a non-pharmacological method to maintain cognitive health for people with dementia.
Alzheimer's disease and other types of dementia are global epidemics, affecting over 40 million people. But due to the complexity of the disease, pharmaceutical developments have had little to no effect on reducing the prevalence of Alzheimer's. Over the past twenty years, more than 200 new drug applications (supported by 450 trials) have been processed in the U.S. However, not one pill received FDA approval.
Mr. Simon Chen, developer of the CST robot, believes a different approach may be the solution during this time.
Mr. Chen says, "many non-pharmacological methods have proven success in preventing cognition decline. Many of these methods can be built into smart robots and we choose the one with most evidence.” The method of choice is Cognitive Stimulation Training, CST.
CST is an evidence-based non-pharmacological method targeting early or mild forms of dementia. The method consists of psychological and social activities which are organized in "sessions" and can spread over a 7- or 14- week period of time. During each session the trainer and the patient engages in either a conversation or an activity. Conversation topics can be chosen by the patient. Available topics span a wide range, including childhood memories, past events, current affairs, and more. Activities include musical bingo, riddles, and thought-provoking number games.
Mr. Chen's plan is to use robot as trainer. He believes the robot-assisted CST program will deliver same benefits as the original CST program does. Reports show improvement in cognition (measured by MMSE or ADAS-cog) and improvement in conducting activities of daily living after 7 weeks of the original CST program.
Mr. Chen's robot is also commissioned to collect research data. The robot will converse with the patient and track the lexical/syntactic features of the patient's speech.
"It is now known that linguistic deficits are viable markers of the disease," Mr. Chen says. "With enough collected data, we can study the linguistic aspects of the disease and share results with the public."
China holds the largest dementia population in the world. Results from this data may lead to a more comprehensive understanding of Alzheimer's and other dementia diseases.
CS Health Tech is an AI technology company devoted to the development of robotic rehab and training therapies for CNS disease individuals. The company is privately held, and has offices in Beijing China and Taipei Taiwan.
Press contact: firstname.lastname@example.org